openPR Logo
Press release

Benign Positional Vertigo Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 // key player - AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A.

04-10-2019 09:26 AM CET | Health & Medicine

Press release from: Fact.MR

Benign Positional Vertigo Treatment Market Scenario

The varied application of benign positional vertigo testing procedures in analyzing/tracking the inner ear and central nervous system and increasing adoption of the treatments in the routine check-ups are harnessing the growth of the Benign Positional Vertigo Treatment Market. However, lack of awareness regarding benign positional vertigo treatments is expected to restrain the growth of the benign positional vertigo treatment market.

Request TOC of this Report- https://www.factmr.com/connectus/sample?flag=T&rep_id=1292

Benign positional vertigo (BPPV) is a sensation of spinning, a form of dizziness. This sensation happens for a few minutes and stops automatically. Benign positional vertigo is related to the labyrinth system which is present inside the inner ear and is responsible for maintaining balance in the body. Sometimes, the free floating particles in the inner ear exert a force to cause benign positional vertigo symptoms. Other causes for benign positional vertigo symptoms include viral infection, nerve inflammation, complications after the ear surgery, side effects of medication and rapid head movement. Nausea, sweating, abnormal eye movements and vomiting are the common symptoms caused by benign positional vertigo. Other symptoms include visual disturbance, hearing loss, and difficulty in speaking and walking. Benign positional vertigo is treated by simple exercises such as Epley maneuver or Brandt–Daroff. Benign positional vertigo treatment is done by the Dix–Hallpike test to determine the posterior semicircular canal involvement and Roll test to check the horizontal semicircular canal involvement. Benign positional vertigo treatment is also done by medications and surgeries. Medication involved in benign positional vertigo treatment by drug class are anti-histamine, anti-cholinergic, and anti-depressant or sedative-hypnotics.

Benign Positional Vertigo Treatment Market: Drivers and Restraints

The growing number of cases of benign positional vertigo is driving the growth of the benign positional vertigo treatment market. Rapid turnaround time, lower cost of procedure over conventional methods also fuel the growth of the benign positional vertigo treatment market. Also, the varied application of benign positional vertigo testing procedures in analyzing/tracking the inner ear and central nervous system and increasing adoption of the treatments in the routine check-ups are harnessing the growth of the benign positional vertigo treatment market. However, lack of awareness regarding benign positional vertigo treatments is expected to restrain the growth of the benign positional vertigo treatment market.

Browse Full Report with TOC- https://www.factmr.com/report/1292/benign-positional-vertigo-treatment-market

According to the International Headache Society and German National Telephone Health Interview Survey 2003, 243 of 1,003 (24%) participants with moderate dizziness/vertigo had a history of vestibular vertigo and 80 (8%) fulfilled the diagnostic criteria for benign positional vertigo (56 women and 24 men; aged 28–82?years). Lifetime prevalence was 3.2% in females, 1.6% in males and 2.4% overall. Medical consultation for benign positional vertigo treatment was reported by 78% of individuals. The 1?year incidence was calculated as 0.6%. Patients usually are seen to prefer internal/general medicine (82%), otolaryngology (57%) and neurology (47%) for benign positional vertigo treatment. As per an article from the International Headache Society survey 2003, 1.1?million adults suffer from BPPV each year in Germany. Japan reported an incidence of BPPV of 0.01% and Olmsted County, Minnesota estimated the incidence of BPPV at 0.06%. Increasing number of patients visiting for benign positional vertigo treatment, and its growing demand exhibits lucrative growth opportunity for the companies operating in the market.

Benign positional vertigo treatment Market: Regional Outlook

Geographically, the global benign positional vertigo treatment market is segmented into regions viz. North America, Europe, Asia-Pacific excluding Japan, Middle East and Africa and Japan. North America & Europe regions are expected to have healthy growth in terms of revenue due to increased awareness regarding benign positional vertigo treatment as a part of the routine checkups. Besides, the lower cost of the procedure compared with other alternative treatments and low risk associated with the procedure are boosting the growth of benign positional vertigo treatment market in the regions.

Benign positional vertigo treatment Market: Key Players

Examples of some of the players identified in the benign positional vertigo treatment market include AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A., Medichem S.A., Liaoyuan Silver Eagle Pharmaceutical Co., Ltd., LGM Pharma, Marclabs and Sun Pharmaceutical Industries Ltd.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Request Brochure of this Report- https://www.factmr.com/connectus/sample?flag=B&rep_id=1292

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Positional Vertigo Treatment Market Scenario Highlighting Major Drivers & Trends, 2018-2028 // key player - AstraZeneca plc., Intas Pharmaceutical Ltd., Cadila Pharmaceuticals, Pfizer Inc., Sanofi S.A. here

News-ID: 1696904 • Views:

More Releases from Fact.MR

Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2034: Fact.MR Report
03-29-2024 | Health & Medicine
Fact.MR
Atrial Fibrillation Device Market to Attain US$ 24.76 Billion at 14.3% CAGR by 2 …
The global atrial fibrillation devices market (心房細動装置市場) size stands at a valuation of US$ 6.52 billion in 2024, with forecasts predicting a surge to US$ 24.76 billion by the conclusion of 2034. Sales of atrial fibrillation devices worldwide are expected to witness an impressive compound annual growth rate (CAGR) of 14.3% from 2024 to 2034. In recent years, the global healthcare landscape has witnessed a significant surge in the prevalence of
Canola Oil Market Rising at 3.6% CAGR to Reach US$ 625 Million by 2032
03-29-2024 | Food & Beverage
Fact.MR
Canola Oil Market Rising at 3.6% CAGR to Reach US$ 625 Million by 2032
The canola oil market is expected to grow at a compound annual growth rate (CAGR) of 3.6% through 2032, from an estimated value of US$ 415 million in 2022 to US$ 625 million by the end of 2032. By the end of 2032, Bunge, ADM, and Louis Dreyfus Company are projected to be the top three producers of canola oil, accounting for around 31% of the global market. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲 𝗖𝗼𝗽𝘆
Digital Experience Platform Market Size to Cross US$ 29.5 Billion at 10.2% CAGR by 2032
Digital Experience Platform Market Size to Cross US$ 29.5 Billion at 10.2% CAGR …
The market for digital experience platforms is expected to expand at a remarkable 10.2% CAGR. It is anticipated to increase from US$ 9.9 billion in 2021 to around US$ 29.5 billion by 2032. A deeper level of customer involvement has been achieved through the evolution of digital customer platform integration, which began with content management systems (CMSs) in the 1980s and web experience management (WEM) solutions in the 1990s. 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗦𝗮𝗺𝗽𝗹𝗲
Fiber Optic Gyroscope Market to Hit US$ 1,760.9 Million with 6.2% CAGR Growth by 2032
Fiber Optic Gyroscope Market to Hit US$ 1,760.9 Million with 6.2% CAGR Growth by …
The fiber optic gyroscopes market is still expanding due to the need for dependable equipment for military and aerospace applications. With a compound annual growth rate (CAGR) of 6.2%, the global fiber optic gyroscope market is projected to reach a valuation of US$ 968.2 million in 2022 and US$ 1,760.9 million by the end of 2032. The market for fiber optic gyroscopes is anticipated to grow as a result of the

All 5 Releases


More Releases for Benign

Benign Prostatic Hyperplasia Therapeutics Market Clinical Survey Report 2020
The Benign Prostatic Hyperplasia Therapeutics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Click the link
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded. Cold plasma isn't in
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports. This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices. Topics Covered Include: An overview of device-based and pharmacological therapies for BPH and prostatitis. Global and country/region-specific market forecasts, including forecasts by product segment. Competitive analyses
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 …
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746 Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a